Advertisement

Pharmacological Treatment of Peptic Ulcer Disease

  • Maciej Sałaga
  • Paula Mosińska
Chapter

Abstract

Peptic ulcer disease (PUD) is an upper gastrointestinal (GI) disorder with complex etiology, which is a growing major concern worldwide. The pathophysiology of PUD is relatively well understood, hence there are several specific treatment options for this disorder aiming at various pharmacological targets located in the GI tract. In this chapter we provide an overview on pharmacological targets as well as drugs that are currently available for PUD therapy with regard to the etiology of the disease. We discuss their mechanisms of action, evidences for their effectiveness emerging from clinical trials as well as virtues and drawbacks of the most commonly prescribed medications. Furthermore, we highlight the practical aspects of the use of drugs in PUD, such as dosing regimens, resistance issues, possible adverse events, and contraindications.

Keywords

Peptic ulcer Gastric ulcer Non-steroidal anti-inflammatory drugs Proton pump inhibitor Prostaglandin Histamine receptor 

Abbreviations

CAM

Complementary and alternative medicine

cAMP

Cyclic AMP

COX

Cyclooxygenase

EP

Prostaglandin type E receptor

GI

Gastrointestinal

GPCR

G protein-coupled receptor

H+/K+ ATPase

Proton pump

H2

Histamine type 2 receptors

NSAIDs

Non-steroidal anti-inflammatory drugs

PPI

Proton pump inhibitor

PUD

Peptic ulcer disease

TNFα

Tumor necrosis factor α

Notes

Acknowledgments

The authors are supported by the Medical University of Lodz [502-03/1-156-04/502-14-140 to MS and #502-03/1-156-04/502-14-299 to PM] and the National Science Centre [#UMO-2015/16/T/NZ7/00031 and #UMO-2013/11/N/NZ7/02354 to MS and #UMO-2016/21/N/NZ5/01932 to PM]. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Disclosures

The authors have nothing to disclose.

Reference

  1. 1.
    Kobayashi T, Inoue I, Jenkins NA, Gilbert DJ, et al. Cloning, RNA expression, and chromosomal location of a mouse histamine H2 receptor gene. Genomics. 1996;37(3):390–4.CrossRefPubMedGoogle Scholar
  2. 2.
    Fukushima Y, Shindo T, Anai M, Saitoh T, et al. Structural and functional characterization of gastric mucosa and central nervous system in histamine H2 receptor-null mice. Eur J Pharmacol. 2003;468(1):47–58.CrossRefPubMedGoogle Scholar
  3. 3.
    Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther. 2004;103(2):147–66.CrossRefPubMedGoogle Scholar
  4. 4.
    Bos CL, Richel DJ, Ritsema T, Peppelenbosch MP, et al. Prostanoids and prostanoid receptors in signal transduction. Int J Biochem Cell Biol. 2004;36(7):1187–205.CrossRefPubMedGoogle Scholar
  5. 5.
    Nighot MP, Nighot PK, Ma TY, Malinowska DH, et al. Genetic ablation of the ClC-2 Cl- channel disrupts mouse gastric parietal cell acid secretion. PLoS One. 2015;10(9):e0138174.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Fujii T, Watanabe M, Shimizu T, Takeshima H, et al. Positive regulation of the enzymatic activity of gastric H(+),K(+)-ATPase by sialylation of its beta-subunit. Biochim Biophys Acta. 2016;1858(6):1228–35.CrossRefPubMedGoogle Scholar
  7. 7.
    Wang J, Barbuskaite D, Tozzi M, Giannuzzo A, et al. Proton pump inhibitors inhibit pancreatic secretion: role of gastric and non-gastric H+/K+-ATPases. PLoS One. 2015;10(5):e0126432.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Ogawa R, Echizen H. Clinically significant drug interactions with antacids: an update. Drugs. 2011;71(14):1839–64.CrossRefPubMedGoogle Scholar
  9. 9.
    Howden CW, Tytgat GN. The tolerability and safety profile of famotidine. Clin Ther. 1996;18(1):36–54.CrossRefPubMedGoogle Scholar
  10. 10.
    Deeks ED. Fixed-dose ibuprofen/famotidine: a review of its use to reduce the risk of gastric and duodenal ulcers in patients requiring NSAID therapy. Clin Drug Investig. 2013;33(9):689–97.CrossRefPubMedGoogle Scholar
  11. 11.
    Yeomans ND, Svedberg LE, Naesdal J. Is ranitidine therapy sufficient for healing peptic ulcers associated with non-steroidal anti-inflammatory drug use? Int J Clin Pract. 2006;60(11):1401–7.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Clark K, Lam LT, Gibson S, Currow D. The effect of ranitidine versus proton pump inhibitors on gastric secretions: a meta-analysis of randomised control trials. Anaesthesia. 2009;64(6):652–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Mills JG, Koch KM, Webster C, Sirgo MA, et al. The safety of ranitidine in over a decade of use. Aliment Pharmacol Ther. 1997;11(1):129–37.CrossRefPubMedGoogle Scholar
  14. 14.
    Aouam K, Bouida W, Ben FN, Chaabane A, et al. Severe ranitidine-induced anaphylaxis: a case report and literature review. J Clin Pharm Ther. 2012;37(4):494–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Foti C, Cassano N, Panebianco R, Calogiuri GF, et al. Hypersensitivity reaction to ranitidine: description of a case and review of the literature. Immunopharmacol Immunotoxicol. 2009;31(3):414–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Davies NM, Longstreth J, Jamali F. Misoprostol therapeutics revisited. Pharmacotherapy. 2001;21(1):60–73.CrossRefPubMedGoogle Scholar
  17. 17.
    Plosker GL, Lamb HM. Diclofenac/misoprostol. Pharmacoeconomic implications of therapy. PharmacoEconomics. 1999;16(1):85–98.CrossRefPubMedGoogle Scholar
  18. 18.
    Pouw RE, Bredenoord AJ. Mistakes in the use of PPIs and how to avoid them. UEG Edu. 2017;17:15–17.Google Scholar
  19. 19.
    Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology. 2000;118(2 Suppl 1):S9–31.CrossRefPubMedGoogle Scholar
  20. 20.
    Thjodleifsson B, Rindi G, Fiocca R, Humphries TJ, et al. A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. Aliment Pharmacol Ther. 2003;17(3):343–51.CrossRefPubMedGoogle Scholar
  21. 21.
    Carling L, Axelsson CK, Forssell H, Stubberod A, et al. Lansoprazole and omeprazole in the prevention of relapse of reflux oesophagitis: a long-term comparative study. Aliment Pharmacol Ther. 1998;12(10):985–90.CrossRefPubMedGoogle Scholar
  22. 22.
    Chang FY, Chiang CY, Tam TN, Ng WW, et al. Comparison of lansoprazole and omeprazole in the short-term management of duodenal ulcers in Taiwan. J Gastroenterol Hepatol. 1995;10(5):595–601.CrossRefPubMedGoogle Scholar
  23. 23.
    Fanti L, Ieri R, Mezzi G, Testoni PA, et al. Long-term follow-up and serologic assessment after triple therapy with omeprazole or lansoprazole of Helicobacter-associated duodenal ulcer. J Clin Gastroenterol. 2001;32(1):45–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Beker JA, Bianchi PG, Bigard MA, Delle FG, et al. Double-blind comparison of pantoprazole and omeprazole for the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol. 1995;7(5):407–10.PubMedGoogle Scholar
  25. 25.
    Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, et al. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study. Aliment Pharmacol Ther. 1999;13(2):179–86.CrossRefPubMedGoogle Scholar
  26. 26.
    Tulassay Z, Kryszewski A, Dite P, Kleczkowski D, et al. One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease. Eur J Gastroenterol Hepatol. 2001;13(12):1457–65.CrossRefPubMedGoogle Scholar
  27. 27.
    Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, et al. Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer--a European multicentre study. The European Rabeprazole Study Group. Aliment Pharmacol Ther. 1998;12(8):789–95.CrossRefPubMedGoogle Scholar
  28. 28.
    Regula J, Butruk E, Dekkers CP, de Boer SY, et al. Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole. Am J Gastroenterol. 2006;101(8):1747–55.CrossRefPubMedGoogle Scholar
  29. 29.
    Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005;294(23):2989–95.CrossRefPubMedGoogle Scholar
  30. 30.
    Lowe DO, Mamdani MM, Kopp A, Low DE, et al. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. Clin Infect Dis. 2006;43(10):1272–6.CrossRefPubMedGoogle Scholar
  31. 31.
    Danziger J, William JH, Scott DJ, Lee J, et al. Proton-pump inhibitor use is associated with low serum magnesium concentrations. Kidney Int. 2013;83(4):692–9.CrossRefPubMedGoogle Scholar
  32. 32.
    William JH, Danziger J. Magnesium deficiency and proton-pump inhibitor use: a clinical review. J Clin Pharmacol. 2016;56(6):660–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Fallone CA, Chiba N, van Zanten SV, Fischbach L, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151(1):51–69.CrossRefPubMedGoogle Scholar
  34. 34.
    Yousfi MM, el-Zimaity HM, al-Assi MT, Cole RA, et al. Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection. Aliment Pharmacol Ther. 1995;9(2):209–12.CrossRefPubMedGoogle Scholar
  35. 35.
    McMahon BJ, Hennessy TW, Bensler JM, Bruden DL, et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med. 2003;139(6):463–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Chen PY, Wu MS, Chen CY, Bair MJ, et al. Systematic review with meta-analysis: the efficacy of levofloxacin triple therapy as the first- or second-line treatments of Helicobacter pylori infection. Aliment Pharmacol Ther. 2016;44(5):427–37.CrossRefPubMedGoogle Scholar
  37. 37.
    Marcus EA, Moshfegh AP, Sachs G, Scott DR. The periplasmic alpha-carbonic anhydrase activity of Helicobacter pylori is essential for acid acclimation. J Bacteriol. 2005;187(2):729–38.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Puscas I. Treatment of gastroduodenal ulcers with carbonic anhydrase inhibitors. Ann N Y Acad Sci. 1984;429:587–91.CrossRefPubMedGoogle Scholar
  39. 39.
    Yang JC, Wang HL, Chern HD, Shun CT, et al. Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication. Pharmacotherapy. 2011;31(3):227–38.CrossRefPubMedGoogle Scholar
  40. 40.
    Sakurai Y, Mori Y, Okamoto H, Nishimura A, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015;42(6):719–30.CrossRefPubMedGoogle Scholar
  41. 41.
    Bi WP, Man HB, Man MQ. Efficacy and safety of herbal medicines in treating gastric ulcer: a review. World J Gastroenterol. 2014;20(45):17020–8.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Lin Y, Liao SS, Zhou YJ. Clinical study on effect of Jianwei Yuyang granule in treating patients with gastric ulcer. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2007;27(7):606–9.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Department of Biochemistry, Faculty of MedicineMedical University of LodzLodzPoland

Personalised recommendations